[ORGANIZATION]
Gilead Sciences Inc.
Featured in 1 tracked story · first seen
Situations
Eli Lilly retatrutide development and black market issues
11 clusters · 32 sources · last updated
Latest: Incretin agonists show potential in obesity treatment amid safety concerns
In early August 2026, Eli Lilly announced that its experimental obesity treatment retatrutide achieved substantial weight-loss outcomes in two phase-3 trials. Participants lost up to 22.6% of body weight over 80 weeks in